Philadelphia Rx Fraud Investigations Have New Chief; Are SEC Cases Next?
Executive Summary
The Philadelphia U.S. Attorney's selection of Virginia Gibson to succeed Jim Sheehan as its Civil Division chief suggests continuity in the office's prescription drug fraud and kickback investigations
You may also be interested in...
Medco SEC Filing For Spin-Off Included “False Statement” On Audit – DoJ Suit
Medco's disclosure of record-keeping problems discovered at its Dallas/Fort Worth pharmacy in an SEC filing included a "false statement," the Philadelphia U.S. Attorney alleges in a complaint filed against the pharmacy benefit management company Sept. 29
Medco SEC Filing For Spin-Off Included “False Statement” On Audit – DoJ Suit
Medco's disclosure of record-keeping problems discovered at its Dallas/Fort Worth pharmacy in an SEC filing included a "false statement," the Philadelphia U.S. Attorney alleges in a complaint filed against the pharmacy benefit management company Sept. 29
Compliance Officers Make Good “Whistleblowers” – U.S. Prosecutor Sheehan
Corporate compliance officers will make up the next wave of "whistleblowers" in health care fraud cases, Philadelphia Associate U.S. Attorney James Sheehan said at the Food & Drug Law Institute Enforcement & Litigation Conference in Washington, D.C. Sept. 22